Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Amgen operates as a global biotechnology pioneer in a single reportable segment: human therapeutics. The company discovers, develops, manufactures, and delivers innovative medicines, with principal products including Repatha, Prolia, EVENITY, TEPEZZA, Otezla, and BLINCYTO.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $8,618 | $8,149 |
| Product Sales | $8,218 | $7,873 |
| Operating Income | $2,666 | $1,178 |
| Net Income | $1,819 | $1,730 |
| Diluted EPS | $3.34 | $3.20 |
| Cash and Cash Equivalents | $12,038 | $8,810 |
| Total Debt (Carrying Value) | $57,323 | $54,604 |
| Operating Cash Flow | $2,189 | $1,391 |
Margins: Operating margin improved significantly to approximately 31% in Q1 2026 compared to 14% in Q1 2025, driven by a reduction in operating expenses.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 6% year-over-year. Product sales grew 4%, driven by 9% volume growth partially offset by a 2% decline in net selling price and inventory destocking.
- Expense Reduction: Total operating expenses decreased 15% to $5.95 billion. This decline was primarily due to the absence of the $800 million Otezla intangible asset impairment charge recorded in Q1 2025 and lower amortization of acquisition-related assets.
- Product Performance:
- Repatha: Sales increased 34% to $876 million, driven by volume growth and favorable sales deductions.
- Prolia & XGEVA: Sales declined 34% and 27% respectively, due to biosimilar competition following patent expirations in the U.S. and Europe.
- TEPEZZA: Sales increased 29% to $490 million, driven by higher inventory and net selling price.
- IMDELLTRA/IMDYLLTRA: Sales surged (change >100%) to $258 million, driven by volume growth.
- Investment Income: Other income, net, decreased significantly to $75 million from $1.5 billion in the prior year, primarily due to net unrealized losses on equity investments (BeOne) in Q1 2026 versus gains in Q1 2025.
Guidance, Outlook, Risks, and Unusual Items
- Regulatory Risks (TAVNEOS): The FDA issued a proposal to withdraw approval of TAVNEOS (avacopan) on April 27, 2026, citing lack of substantial evidence of effectiveness and alleged untrue statements in the original application. The company intends to contest this proposal. TAVNEOS remains on the market during the process.
- Tax Litigation: Amgen is engaged in significant ongoing litigation with the IRS regarding profit allocation between U.S. and Puerto Rico entities for tax years 2010–2015. A decision from the U.S. Tax Court is expected no earlier than the second half of 2026. A draft notice of proposed adjustment for years 2016–2018 was received in April 2026.
- Pricing Policy: The company is navigating the Inflation Reduction Act (IRA) and the Most-Favored-Nations (MFN) Executive Order. ENBREL is subject to Medicare price setting effective January 1, 2026, and Otezla is selected for price setting beginning in 2027.
- Capital Allocation: In Q1 2026, Amgen issued $4.0 billion in new debt and repaid $833 million in maturing debt. No shares were repurchased under the stock repurchase program, with $6.8 billion of authorization remaining. Dividends were declared at $2.52 per share.
- Unusual Items: Q1 2025 included an $800 million impairment charge for Otezla intangible assets, which is not present in Q1 2026, distorting year-over-year expense comparisons.
Investor Verification Checklist
- TAVNEOS Regulatory Status: Monitor the outcome of the FDA's proposal to withdraw approval and the company's legal response, as this could impact future revenue and intangible asset valuations.
- IRS Tax Dispute Resolution: Track the U.S. Tax Court decision expected in H2 2026 and the status of the 2016–2018 audit, as adverse outcomes could result in billions in additional tax liabilities.
- Biosimilar Erosion: Verify the trajectory of sales declines for Prolia and XGEVA as biosimilar competition intensifies in the U.S. and ROW markets.
- BeOne Investment Volatility: Review the fair value adjustments of the BeOne equity investment, which caused significant volatility in "Other income, net" between Q1 2025 and Q1 2026.
- IRA and MFN Impact: Assess the long-term financial impact of Medicare price setting on ENBREL and Otezla, and the potential effects of MFN pricing agreements on global net sales.